{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson's disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant, linking LRRK2 mutations to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain, focusing on the high stoichiometry S935 phosphorylation site.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used (phosphorylation and protein interaction assays) effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study used anti-pS935 specific antibody to show that LRRK2 is constitutively phosphorylated at S935 in various tissues and at different ages in mice. It also identified 14-3-3 proteins binding to LRRK2, depending on phosphorylation of S935.",
          "judgment": "Yes",
          "reasoning": "The paper describes the use of specific antibodies and controls (e.g., S935A mutant) to validate the assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study shows that common PD-related mutations of LRRK2, including R1441G, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The study uses known pathogenic variants as controls and shows that the R1441G mutation affects phosphorylation and 14-3-3 binding, similar to other pathogenic mutations.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study indicates that the R1441G mutation causes a marked reduction of pS935 levels and 14-3-3 binding, consistent across various assays.",
          "judgment": "Yes",
          "reasoning": "The evidence supports a pathogenic effect of the R1441G mutation through impaired phosphorylation and 14-3-3 binding, key regulatory mechanisms of LRRK2.",
          "next_step_or_outcome": "Final assessment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The R1441G mutation in LRRK2 is associated with reduced phosphorylation at S935 and impaired 14-3-3 binding, consistent with pathogenic mechanisms in PD. The evidence supports a moderate strength PS3 classification due to the consistent findings across assays and the use of pathogenic variant controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are linked to the most common familial form and some sporadic forms of PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly links LRRK2 mutations to PD, defining the disease mechanism relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study focused on the phosphorylation of LRRK2 at S935 and its interaction with 14-3-3 proteins.",
          "judgment": "Yes",
          "reasoning": "The assays used (phosphorylation and protein interaction) are relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study demonstrated that the Y1699C mutation reduces pS935 levels and 14-3-3 binding.",
          "judgment": "Yes",
          "reasoning": "The study provides evidence of the mutation's effect on phosphorylation and protein binding, using appropriate controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The Y1699C mutation was shown to impair phosphorylation and 14-3-3 binding, similar to other pathogenic mutations.",
          "judgment": "Yes",
          "reasoning": "The study uses pathogenic variants as controls, supporting the pathogenic effect of Y1699C.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The Y1699C mutation consistently reduces pS935 levels and 14-3-3 binding across assays.",
          "judgment": "Yes",
          "reasoning": "The evidence supports a pathogenic role for Y1699C through impaired regulatory mechanisms of LRRK2.",
          "next_step_or_outcome": "Final assessment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The Y1699C mutation in LRRK2 leads to reduced phosphorylation at S935 and impaired 14-3-3 binding, aligning with pathogenic mechanisms in PD. The consistent findings across assays support a moderate strength PS3 classification."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with familial and sporadic PD.",
          "judgment": "Yes",
          "reasoning": "The paper establishes the link between LRRK2 mutations and PD, defining the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study examined the effect of G2019S on S935 phosphorylation and 14-3-3 binding.",
          "judgment": "Yes",
          "reasoning": "The assays used are appropriate for investigating the pathogenic mechanisms of LRRK2 mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The G2019S mutation showed a modest decrease in pS935 levels in transgenic brain but little effect in cell culture.",
          "judgment": "Yes",
          "reasoning": "The study provides evidence of the mutation's effect, though the impact varies by assay system.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The G2019S mutation was compared to other pathogenic mutations, showing a modest reduction in 14-3-3 binding.",
          "judgment": "Yes",
          "reasoning": "The use of pathogenic variant controls supports the assessment of G2019S's pathogenic potential.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The G2019S mutation's effect on phosphorylation and 14-3-3 binding is modest and assay-dependent.",
          "judgment": "Yes",
          "reasoning": "The evidence suggests a pathogenic role for G2019S, though the effect is less pronounced than for other mutations.",
          "next_step_or_outcome": "Final assessment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S mutation in LRRK2 has a modest effect on S935 phosphorylation and 14-3-3 binding, suggesting a pathogenic role in PD. The variability in assay results supports a supporting strength PS3 classification."
    }
  ]
}